While Sorafenib which forms a π-cation interaction with the lysine residue of the human p38 MAP kinase was approved for the treatment of liver cancer, lysine residue of ErbB4 kinase having π-cation interaction with lapatinib was approved for the treatment of breast cancer (63, 64). Here, MAPK14 is linked to breast carcinoma.